Glaucoma Treatments in 2021: Personalizing Patient Needs

This activity is supported by an unrestricted educational grant from Bausch + Lomb.

Learning Objectives

Upon completion of this activity, the participant should be able to:

• Describe the mechanisms of action of novel therapeutics and classes of drugs for ocular hypertension (OHT) and primary open angle glaucoma (POAG)
• Interpret the challenges and limitations associated with currently available pharmacologic treatment options for OHT and POAG
• Evaluate monotherapy and combination regimens and compare which option is most likely to achieve each individual patient’s goal IOP
• Compare and assess the efficacy of novel therapeutics with traditional prostaglandins

Accreditation and Designation Statement

This educational activity is provided by Evolve Medical Education LLC (Evolve).

Accreditation Statement
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsored by

Evolve Medical Education LLC (Evolve) is an approved COPE administrator.

This activity, COPE Activity Number 122971, is accredited by COPE for continuing education for optometrists. 
This course is approved for 1 hour of CE. 

Course # 75406-GL
Activity # 122971

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Nathan M. Radcliffe, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Alcon Vision, Alimera Sciences, Allergan, Bausch + Lomb, Beaver-Visitec International, Carl Zeiss Meditec, CATS, Ellex, ELT Sight, Equinox, Eyepoint Pharmaceuticals, Glaukos, Iridex, Ivantis/Kala Pharmaceuticals, Lumenis, New World Medical, Novartis, Ocular Science, Ocular Therapeutix, Omeros, Quantel Medical, Reichert, Santen, Shire Sight Sciences, Spyglass Thea, and ViaLase. Speaker’s Bureau: Aerie Pharmaceuticals, Alcon Vision, Alimera Sciences, Allergan, Bausch + Lomb, Beaver-Visitec International, Eyepoint Pharmaceuticals, Glaukos, Iridex, Ivantis\Kala Pharmaceuticals, Lumenis, New World Medical, Novartis, Reichert, and Sight Sciences. Stock/Shareholder: CATS, ELT Sight, Equinox, Ivantis, Sight Sciences, and Spyglass.

Jason Bacharach, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research: Allergan, Glaukos, Nicox, Ocular Therapeutix, and Santen. Consultant: Aerie Pharmaceuticals, Allergan, Bausch + Lomb, Glaukos, and Santen. Speaker’s Bureau: Aerie Pharmaceuticals, Allergan, and Bausch + Lomb. Shareholder: Injectsense.

Murray Fingeret, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Heidelberg, and Topcon. Speaker’s Bureau: Aerie Pharmaceuticals.

Lorraine M. Provencher, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Ivantis, and Visus. Speaker’s Bureau: Allergan and MST.

The Evolve staff and planners have no financial relationships with commercial interests. Michelle Dalton, writer, and Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Glaucoma Today, Modern Optometry, or Bausch + Lomb.